Efficacy and safety of orforglipron, an oral small-molecule GLP-1 receptor agonist, on cardiometabolic outcomes: a meta-analysis and systematic review - PubMed
9 hours ago
- #Cardiometabolic risk
- #Type 2 diabetes
- #Oral GLP-1 receptor agonist
- Orforglipron is a novel once-daily oral non-peptide GLP-1 receptor agonist designed for cardiometabolic risk reduction.
- The meta-analysis shows orforglipron significantly improves cardiovascular risk factors: body weight (−6.08%), HbA1c (−0.85%), systolic blood pressure (−4.32 mmHg), LDL-cholesterol (−4.14%), triglycerides (−10.90%), and increases HDL-cholesterol (+3.31%).
- Gastrointestinal side effects are common but typical of GLP-1 receptor agonists (nausea RR 5.22, vomiting RR 3.24, eructation RR 6.80).
- Orforglipron offers a transformative option for ASCVD prevention in patients with obesity and type 2 diabetes, with effect sizes comparable to injectable GLP-1 receptor agonists.